J 2024

Non-Coding RNAs in Peritoneal Carcinomatosis: From Bench to Bedside

BOHOŠOVÁ, Júlia, Nida Sarosh ASHRAF, Ondřej SLABÝ a George A CALIN

Základní údaje

Originální název

Non-Coding RNAs in Peritoneal Carcinomatosis: From Bench to Bedside

Autoři

BOHOŠOVÁ, Júlia (703 Slovensko, domácí), Nida Sarosh ASHRAF, Ondřej SLABÝ (203 Česká republika, domácí) a George A CALIN

Vydání

Cancers, BASEL, MDPI, 2024, 2072-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.200 v roce 2022

Organizační jednotka

Lékařská fakulta

UT WoS

001310985100001

Klíčová slova anglicky

peritoneal carcinomatosis; non-coding RNA; miRNA; ascites; exosomes

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 1. 10. 2024 11:07, Mgr. Tereza Miškechová

Anotace

V originále

Simple Summary Peritoneal carcinomatosis is a term for cancer cells spreading from tumors of internal organs and massively invading a large part of the membrane lining the abdomen and pelvis. For most patients, peritoneal carcinomatosis suggests only several months of life left. Current medicine can offer only alleviation of symptoms from this incurable disease. Researchers are intensely exploring some new therapeutic targets. Among promising candidates are non-coding RNAs, short molecules serving as important regulators in cells. When a disease such as cancer develops in the body, it is accompanied by typical changes in levels of non-coding RNAs. In this review, we provide an overview of current state of knowledge regarding the changes of non-coding RNA levels in peritoneal carcinomatosis. Deeper understanding of this topic could lead to the identification of non-coding RNAs as feasible specific biomarkers or novel therapeutic targets in the treatment of peritoneal carcinomatosis.Abstract Peritoneal carcinomatosis represents an advanced stage of tumors within the peritoneal cavity. Once considered an incurable terminal cancer metastasis, contemporary medicine is on the hunt for certain potentially curative options alongside the present day's palliative disease management. However, for most patients, peritoneal carcinomatosis continues to pose a fatal late-stage prognosis with a grim future outlook. Over the past two decades, non-coding RNAs have garnered significant attention due to their undeniable significance in regulating cellular processes across all levels. Disruption of the intricate regulation led by non-coding RNAs has been demonstrated to have a substantial impact on various human diseases, particularly in cancer, including solid tumors originating from the organs of the peritoneal cavity. This review aims to offer a comprehensive overview of the current state of knowledge in the under-researched field of peritoneal carcinomatosis, focusing specifically on the role of non-coding RNAs in the development of this condition and delineating potential avenues for future research.

Návaznosti

824036, interní kód MU
Název: Excellence in research and development of non-coding RNA DIAGnostics in ONcology (Akronym: RNADIAGON)
Investor: Evropská unie, Excellence in research and development of non-coding RNA DIAGnostics in ONcology, MSCA Marie Skłodowska-Curie Actions (Excellent Science)